Novus Biologicals products are now on bio-techne.com

CCL5/RANTES Antibody [Biotin]

Images

 
Impact of prolonged stimulation by Tumor CM on the release of inflammatory chemokines by the resulting CAFs. Human BM-derived MSCs were cultured with Tumor CM from MDA-MB-231 cells (MDA) (A) or MCF-7 cells (B) over a ...read more
Basal and cytokine-induced release of inflammatory chemokines by patient CAFs. CAFs were isolated from lung metastasis of a breast cancer patient (CAFs #1) or from a primary tumor of a different breast cancer patient ...read more

Product Details

Summary
Reactivity Hu, PmSpecies Glossary
Applications WB, ELISA(Det)
Clonality
Polyclonal
Host
Goat
Conjugate
Biotin
Concentration
LYOPH

Order Details

View Available Conjugates
Catalog# & Conjugate Size Price
View Available Formulations
Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

CCL5/RANTES Antibody [Biotin] Summary

Immunogen
E. coli-derived recombinant human CCL5/RANTES
Ser24-Ser91
Accession # P13501
Specificity
Detects human and primate CCL5/RANTES in ELISAs and Western blots.  In sandwich immunoassays, approximately 12% cross‑reactivity with rmCCL5 is observed and less than 0.05% cross‑reactivity with rhIL-8, rhGRO alpha , rhMCP-1, rhMIP-1 alpha and rhMIP‑1 beta is observed.
Source
N/A
Isotype
IgG
Clonality
Polyclonal
Host
Goat
Gene
CCL5
Purity Statement
Antigen Affinity-purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.

Applications/Dilutions

Dilutions
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 0.1 ug/mL
Application Notes
ELISA Capture: Human CCL5/RANTES Antibody (Catalog # MAB678)
ELISA Detection: Human CCL5/RANTES Biotinylated Antibody (Catalog # BAF278)
Standard: Recombinant Human CCL5/RANTES (Catalog # 278-RN)
Readout System
Publications
Read Publications using
BAF278 in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Preservative
No Preservative
Concentration
LYOPH
Reconstitution Instructions
Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL5/RANTES Antibody [Biotin]

  • CCL5
  • chemokine (C-C motif) ligand 5
  • D17S136Enormally T-expressed, and presumably secreted
  • EoCP
  • Eosinophil chemotactic cytokine
  • RANTES
  • SISd
  • SIS-delta
  • small inducible cytokine A5 (RANTES)
  • small inducible cytokine subfamily A (Cys-Cys), member 5
  • Small-inducible cytokine A5
  • T cell-specific protein P228
  • T-cell specific protein p288
  • TCP228T-cell-specific protein RANTES

Background

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1 - 3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature human CCL5 shares 75% - 84% aa seqeuence identity with canine, cotton rat, feline, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11 - 13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14 - 16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).

  1. Schall, T.J. et al. (1990) Nature 347:669.
  2. Bacon, K.B. et al. (1995) Science 269:1727.
  3. Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
  4. Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
  5. Schall, T.J. et al. (1988) J. Immunol. 141:1018.
  6. Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
  7. Levy, J.A. (2009) J. Immunol. 182:3945.
  8. Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
  9. DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
  10. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
  11. Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
  12. Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
  13. von Hundelshausen, P. et al. (2005) Blood 105:924.
  14. von Hundelshausen, P. et al. (2001) Circulation 103:1772.
  15. Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
  16. Baltus, T. et al. (2003) Blood 102:1985.
  17. Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customers Who Viewed This Item Also Viewed...

DCP00
Species: Hu
Applications: ELISA
M6000B
Species: Mu
Applications: ELISA
DIP100
Species: Hu
Applications: ELISA
MAB182
Species: Hu
Applications: CyTOF-ready, Flow, ICC, Neut
MAB208
Species: Hu
Applications: CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta), ICC, ICFlow, Neut, Simple Western, WB
MME00
Species: Mu
Applications: ELISA
DY417
Species: Mu
Applications: ELISA
6507-IL/CF
Species: Hu
Applications: BA
MMA00
Species: Mu
Applications: ELISA
NBP1-19371
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
MAB145
Species: Hu
Applications: CyTOF-ready, Flow
202-IL
Species: Hu
Applications: BA
M5000
Species: Mu
Applications: ELISA
AF-492-NA
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut
NB100-56583
Species: Hu, Rb, Rt
Applications: Flow, IHC, IHC-P, KO, WB
DMB00
Species: Hu
Applications: ELISA

Publications for CCL5/RANTES Antibody (BAF278)(32)

We have publications tested in 2 confirmed species: Human, Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque).

We have publications tested in 8 applications: ELISA Capture, ELISA Detection, ELISA Development, ELISA Microarray Development, ICC, IHC, Luminex Development, Western Blot.


Filter By Application
ELISA Capture
(2)
ELISA Detection
(4)
ELISA Development
(11)
ELISA Microarray Development
(1)
ICC
(2)
IHC
(1)
Luminex Development
(3)
Western Blot
(1)
All Applications
Filter By Species
Human
(24)
Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque)
(1)
All Species
Showing Publications 1 - 10 of 32. Show All 32 Publications.
Publications using BAF278 Applications Species
S Lee, YJ Seo, JY Choi, X Che, HJ Kim, SY Eum, MS Hong, SK Lee, DC Cho Effect of teriparatide on drug treatment of tuberculous spondylitis: an experimental study Scientific Reports, 2022-12-15;12(1):21667. 2022-12-15 [PMID: 36522387] (ELISA Detection, Human) ELISA Detection Human
S Guerrero, E Sánchez-Ti, L Agüí, A González-C, P Yáñez-Sede, JM Pingarrón Development of an Electrochemical CCL5 Chemokine Immunoplatform for Rapid Diagnosis of Multiple Sclerosis Biosensors, 2022-08-07;12(8):. 2022-08-07 [PMID: 36005006] (ELISA Capture, Human) ELISA Capture Human
T Baram, N Oren, N Erlichman, T Meshel, A Ben-Baruch Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFalpha Receptors in Human Triple-Negative Breast Cancer Cancers, 2022-07-19;14(14):. 2022-07-19 [PMID: 35884574] (ELISA Capture, Human) ELISA Capture Human
N Erlichman, T Baram, T Meshel, D Morein, B Da'adoosh, A Ben-Baruch Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes Cancers, 2022-02-18;14(4):. 2022-02-18 [PMID: 35205789] (ELISA Detection, Human) ELISA Detection Human
C Kötting, L Hofmann, R Lotfi, D Engelhardt, S Laban, PJ Schuler, TK Hoffmann, C Brunner, MN Theodoraki Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma Cancers, 2021-03-16;13(6):. 2021-03-16 [PMID: 33809574] (ELISA Detection, Human) ELISA Detection Human
Mehdi Bouhaddou, Danish Memon, Bjoern Meyer, Kris M. White, Veronica V. Rezelj, Miguel Correa Marrero et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection Cell 8/1/2020 [PMID: 32645325]
PS Arunachala, TP Charles, V Joag, VS Bollimpell, MKD Scott, F Wimmers, SL Burton, CC Labranche, C Petitdeman, S Gangadhara, TM Styles, CF Quarnstrom, KA Walter, TJ Ketas, T Legere, PB Jagadeesh, SP Kasturi, A Tsai, BZ Yeung, S Gupta, M Tomai, J Vasilakos, GM Shaw, CY Kang, JP Moore, S Subramania, P Khatri, D Montefiori, PA Kozlowski, CA Derdeyn, E Hunter, D Masopust, RR Amara, B Pulendran T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers Nat. Med., 2020-05-11;0(0):. 2020-05-11 [PMID: 32393800] (ELISA Detection, Human) ELISA Detection Human
SK Singh, MK Mishra, BM Rivers, JB Gordetsky, S Bae, R Singh Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma Cancers (Basel), 2020-04-05;12(4):. 2020-04-05 [PMID: 32260550] (IHC, Human) IHC Human
Yulia Liubomirski, Shalom Lerrer, Tsipi Meshel, Dina Morein, Linor Rubinstein-Achiasaf, David Sprinzak et al. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer Frontiers in Immunology 4/24/2019 [PMID: 31105691]
Yulia Liubomirski, Shalom Lerrer, Tsipi Meshel, Linor Rubinstein-Achiasaf, Dina Morein, Stefan Wiemann et al. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer Frontiers in Immunology 4/12/2019 [PMID: 31031757]
Show All 32 Publications.

Reviews for CCL5/RANTES Antibody (BAF278) (0)

There are no reviews for CCL5/RANTES Antibody (BAF278). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

Video Protocols

WB Video Protocol

FAQs for CCL5/RANTES Antibody (BAF278) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.
mFluor Violet Conjugated Antibodies

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our CCL5/RANTES Antibody [Biotin] and receive a gift card or discount.

Bioinformatics

Gene Symbol CCL5
Uniprot